Royal Bank Of Canada Sellas Life Sciences Group, Inc. Transaction History
Royal Bank Of Canada
- $479 Billion
- Q4 2024
A detailed history of Royal Bank Of Canada transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 200 shares of SLS stock, worth $236. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$236
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding SLS
# of Institutions
38Shares Held
7.08MCall Options Held
1.8MPut Options Held
49.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.71 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX1.19MShares$1.41 Million0.16% of portfolio
-
Geode Capital Management, LLC Boston, MA734KShares$865,5840.0% of portfolio
-
Brooklyn Fi, LLC New York, NY595KShares$702,0040.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il485KShares$572,6740.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.3M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...